Al Freedman, PhD, a psychologist who specializes in rare disease communities, discusses how to manage social isolation while living with amyotrophic lateral sclerosis (ALS). He shares his background as a father to his late son Jack, who had spinal muscular atrophy (SMA), and how his role as a caregiver has…
The U.S. Food and Drug Administration (FDA) has granted fast track status to usnoflast, Zydus Lifesciences’ experimental oral inhibitor, for treating amyotrophic lateral sclerosis (ALS). The designation is meant to accelerate the development and review of new therapies that address unmet medical needs in serious or life-threatening conditions, and…
His ALS diagnosis made Air Force Veteran Michael focus on what matters most to him—strengthening his relationships with his children. Hear more about how he generates hope for others with ALS so they can stay in the fight. This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and…
As a former pastor and chaplain, Deb found the strength to transform the fear and frustration from her diagnosis into hope and help for others with ALS. Discover how Deb learned to celebrate every new day as a gift.
Eugene was used to motivating others to be the best by giving their all. But when an ALS diagnosis knocked him to his knees, he rallied to find new ways to move forward. Learn about Eugene's game plan for living with ALS.
MN-166 (ibudilast) is an experimental oral therapy that’s designed to reduce inflammation and protect nerve cells from damage in people with ALS. Developed by MediciNova, it’s expected to slow disease progression.
When ALS impacted RocÃo's husband Francisco, she knew the disease couldn't shake their greatest source of love and support—their family. Hear how they worked together to get Francisco the understanding and treatment he needed.
Neuvivo’s investigational therapy NP001 (sodium chlorite), designed to dampen inflammation and restore immune system balance, extended survival in people with amyotrophic lateral sclerosis (ALS), according to an combined analysis of data, spanning up to 11 years, on patients who took part in either of two Phase 2…
NeuroSense Therapeutics has initiated the process of applying to Canada’s regulators for early marketing approval of PrimeC in treating amyotrophic lateral sclerosis (ALS), based on positive findings in a Phase 2b clinical trial. The application will be filed under Health Canada’s Notice of Compliance with Conditions policy, which could…
A home-based multidisciplinary care model for people living with amyotrophic lateral sclerosis (ALS) was found feasible, and was rated as highly satisfactory by both patients and caregivers, according to a pilot study conducted in Germany. The care model also helped patients avoid hospitalizations and remain at home during the…
